Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS
- 1.3k Downloads
In the 12-month phase 3 TRANSFORMS study, fingolimod showed greater efficacy than intramuscular interferon beta (IFNβ)-1a in patients with relapsing–remitting multiple sclerosis (RRMS). This study analyzed fingolimod efficacy compared with IFNβ-1a in patient subgroups from TRANSFORMS. Patients were randomized to receive fingolimod or weekly IM IFNβ-1a for 12 months. Analyses of efficacy included annualized relapse rate (ARR), and magnetic resonance imaging (MRI) measures [gadolinium (Gd)-enhancing T1 lesions, new/newly enlarged (active) T2 lesions, brain volume change]. Subgroups were defined based on demographics, disease characteristics (baseline EDSS score, relapse rate, and MRI parameters), and response to previous therapy. Fingolimod 0.5 mg reduced ARR over 12 months by 32–59 % relative to IFNβ-1a in all subgroups defined by demographic factors or baseline disease characteristics. Fingolimod also reduced the number of new Gd-enhancing lesions, active T2 lesions, and the rate of brain volume loss, versus IFNβ-1a in most (95 %) subgroups. In patients with high disease activity despite IFNβ treatment in the year before study, fingolimod 0.5 mg reduced ARR by 61 % relative to IFNβ-1a. Reductions in lesion counts and brain volume loss also favored fingolimod in these patients. In conclusion, consistently better efficacy was observed for fingolimod compared with IFNβ-1a across different subgroups of patients with RRMS.
KeywordsMultiple sclerosis Randomized clinical trial Fingolimod Interferon-beta MRI Subgroup analysis
The authors thank the patients who participated in the study, the study site personnel, and C. Brechin PhD (Oxford PharmaGenesis™ Ltd) and H. Salloukh (Novartis Pharma AG) for editorial assistance. All authors had full access to all data in the study, participated in writing the manuscript, and approved the full manuscript before the corresponding author took final responsibility for the decision to submit for publication. This study was funded by Novartis Pharma AG, Basel, Switzerland.
Conflicts of interest
Prof. Cohen has received reimbursement for travel or consulting from Biogen Idec, Elan, Novartis, Teva, and Vaccinex. He has also received research support paid to his institution from Biogen Idec, Novartis, Receptos, Teva, Synthon, and Vaccinex. Dr. Barkhof has received consultancy fees from Bayer Schering Pharma, Sanofi-Aventis, Biogen Idec, GE Medical Systems, Genzyme, Synthon, Novartis and Roche. He has served as an editorial board member for Brain, Journal of Neurology, European Radiology and Neuroradiology. He has received payment for speaker services from Novartis and Serono. Barkhof has also received research support from the Dutch Foundation for MS Research. Prof. Comi has received consulting fees for speaker services from Novartis, Teva Pharmaceutical Industries, Sanofi-Aventis, Merck Serono, Bayer and Actelion. He has also received lecture fees from Novartis, Teva Pharmaceutical Industries, Sanofi-Aventis, Merck Serono, Biogen Dompè, Bayer and Serono Symposia International Foundation. Prof. Izquierdo has received payment for board membership of Biogen, Novartis, Sanofi, Serono and Teva. He has also received consultancy fees or honorarium from Biogen Idec, Merck, Bayern, Sanofi, Teva and Novartis. Dr. Khatri has received consultancy fees from Teva, Biogen Idec, Bayer, Pfizer, Genzyme, Questcor, Avanit, Novartis and Teurimo BCT. He has received research support from Biogen Idec and Novartis. Dr. Montalban has received speaking honoraria and travel expenses for scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past years with Bayer Schering Pharma, Biogen Idec, EMD Merck Serono, Genentech, Genzyme, Novartis, Sanofi-Aventis, Teva Pharmaceutical Industries and Almirall. Prof. Pelletier has received payment for scientific advisory boards for Allergan, Bayer Schering Pharma, Biogen Idec, Genzyme, Merck Serono, Novartis, Sanofi and Teva. He has received non-profit foundation support from ARSEP, academic research support from PHRC, and unconditional research support from Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, Sanofi and Teva. Dr. Eckert is an employee of Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Dr. Häring is an employee of Novartis Pharma AG, Basel, Switzerland. Dr. Francis is an employee of Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
- 1.Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402–415PubMedCrossRefGoogle Scholar
- 3.Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA (2011) Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 10(6):520–529PubMedCrossRefGoogle Scholar
- 9.Devonshire V, Havrdova E, Radue EW, O’Connor P, Zhang-Auberson L, Agoropoulou C, Haring DA, Francis G, Kappos L (2012) Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol 11(5):420–428PubMedCrossRefGoogle Scholar
- 15.Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39(3):285–294PubMedCrossRefGoogle Scholar
- 16.Li DK, Paty DW (1999) Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol 46(2):197–206PubMedCrossRefGoogle Scholar
- 17.PRISMS study group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) Study Group. Lancet 352(9139):1498–1504CrossRefGoogle Scholar